Clinical and Experimental Reproductive Medicine

  • 제51권3호
  • /
  • Pages.181-191
  • /
  • 2024
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Systematic review of the roles of inositol and vitamin D in improving fertility among patients with polycystic ovary syndrome

  • Gitika Katyal (California Institute of Behavioral Neurosciences and Psychology) ;
  • Gursharan Kaur (California Institute of Behavioral Neurosciences and Psychology) ;
  • Hafsa Ashraf (California Institute of Behavioral Neurosciences and Psychology) ;
  • Adiprasad Bodapati (California Institute of Behavioral Neurosciences and Psychology) ;
  • Ayesha Hanif (California Institute of Behavioral Neurosciences and Psychology) ;
  • Donatus Kaine Okafor (California Institute of Behavioral Neurosciences and Psychology) ;
  • Safeera Khan (California Institute of Behavioral Neurosciences and Psychology)
  • 투고 : 2023.09.15
  • 심사 : 2023.12.20
  • 발행 : 2024.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder among reproductive-age women. As a leading cause of anovulatory infertility, it complicates fertility treatments, including in vitro fertilization. The widely accepted 2003 Rotterdam diagnostic criteria for PCOS include sub-phenotypes based on variations in androgen excess, ovulatory dysfunction, and polycystic ovarian morphology. In this systematic review, we examined the impacts of inositol and vitamin D on fertility in PCOS. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, we used relevant keywords to comprehensively search databases including PubMed, Google Scholar, and MDPI. From an initial pool of 345 articles, 10 met the inclusion criteria. The articles suggest that vitamin D and inositol, particularly myo-inositol and D-chiro-inositol, may represent therapeutic options for PCOS. Vitamin D influences ovarian follicular development, glucose regulation, and insulin sensitivity. When combined with metformin therapy, it is associated with improved menstrual regularity and ovulation. Inositol is crucial for cellular signaling, energy metabolism, glucose regulation, and fertility. This systematic review underscores the importance of investigating inositol and vitamin D within a PCOS management strategy, given the disorder's prevalence and impacts on fertility and metabolic health. Although these agents show promise, additional research could clarify their mechanisms of action and therapeutic benefits. This review emphasizes the need for exploration of effective treatments to improve the quality of life among individuals with PCOS. Inositol and vitamin D represent potential options, but more studies are required to elucidate their roles in the management of this condition.

키워드

참고문헌

  1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018;14:270-84. https://doi.org/10.1038/nrendo.2018.24
  2. El-Berry S, Razik MA. Nitric oxide donors increases pregnancy rate in clomiphene citrate treated polycystic ovary infertile patients. Middle East Fertil Soc J 2010;15:106-9. https://doi.org/10.1016/j.mefs.2010.04.004
  3. Amjadi F, Mehdizadeh M, Ashrafi M, Nasrabadi D, Taleahmad S, Mirzaei M, et al. Distinct changes in the proteome profile of endometrial tissues in polycystic ovary syndrome compared with healthy fertile women. Reprod Biomed Online 2018;37:184-200. https://doi.org/10.1016/j.rbmo.2018.04.043
  4. Chen S, Song J. Oocyte quality and embryo quality of infertile women with polycystic ovarian syndrome. Fertil Steril 2008;90(Suppl):S132.
  5. Christ JP, Cedars MI. Current guidelines for diagnosing PCOS. Diagnostics (Basel) 2023;13:1113.
  6. Lin MW, Wu MH. The role of vitamin D in polycystic ovary syndrome. Indian J Med Res 2015;142:238-40. https://doi.org/10.4103/0971-5916.166527
  7. Gambioli R, Forte G, Buzzaccarini G, Unfer V, Lagana AS. Myo-inositol as a key supporter of fertility and physiological gestation. Pharmaceuticals (Basel) 2021;14:504.
  8. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 2019;4:5.
  9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
  10. Azhar A, Abid F, Rehman R. Polycystic ovary syndrome, subfertility and vitamin D deficiency. J Coll Physicians Surg Pak 2020;30:545-6. https://doi.org/10.29271/jcpsp.2020.05.545
  11. Artini PG, Malacarne E, Tomatis V, Genazzani AD. The relevance of inositols treatment for PCOS before and during ART. Eur Rev Med Pharmacol Sci 2021;25:4799-809.
  12. Wojciechowska A, Osowski A, Jozwik M, Gorecki R, Rynkiewicz A, Wojtkiewicz J. Inositols' importance in the improvement of the endocrine-metabolic profile in PCOS. Int J Mol Sci 2019;20:5787.
  13. Mu Y, Cheng D, Yin TL, Yang J. Vitamin D and polycystic ovary syndrome: a narrative review. Reprod Sci 2021;28:2110-7. https://doi.org/10.1007/s43032-020-00369-2
  14. Mendoza N, Galan MI, Molina C, Mendoza-Tesarik R, Conde C, Mazheika M, et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol 2020;36:398-401. https://doi.org/10.1080/09513590.2019.1681959
  15. Akbari Sene A, Tabatabaie A, Nikniaz H, Alizadeh A, Sheibani K, Mortezapour Alisaraie M, et al. The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Arch Gynecol Obstet 2019;299:1701-7. https://doi.org/10.1007/s00404-019-05111-1
  16. Prabhakar P, Mahey R, Gupta M, Khadgawat R, Kachhawa G, Sharma JB, et al. Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol 2021;37:332-6. https://doi.org/10.1080/09513590.2020.1810657
  17. Pourghasem S, Bazarganipour F, Taghavi SA, Kutenaee MA. The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. Arch Gynecol Obstet 2019;299:1193-9. https://doi.org/10.1007/s00404-019-05064-5
  18. Lejman-Larysz K, Golara A, Baranowska M, Kozlowski M, Guzik P, Szydlowska I, et al. Influence of vitamin D on the incidence of metabolic syndrome and hormonal balance in patients with polycystic ovary syndrome. Nutrients 2023;15:2952.
  19. Gokosmanoglu F, Onmez A, Ergenc H. The relationship between Vitamin D deficiency and polycystic ovary syndrome. Afr Health Sci 2020;20:1880-6. https://doi.org/10.4314/ahs.v20i4.45
  20. Sigue RJL, Decena DD. Efficacy of Myo-inositol in improving pregnancy rate and regulation of menstrual cycle for patients with polycystic ovarian syndrome: a systematic review and meta-analysis. J Med Univ St Tomas 2022;6:979-98.
  21. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, editors. Polycystic ovary syndrome. Blackwell Scientific; 1992. p. 377-84.
  22. Vitale SG, Rossetti P, Corrado F, Rapisarda AM, La Vignera S, Condorelli RA, et al. How to achieve high-quality oocytes? The key role of myo-inositol and melatonin. Int J Endocrinol 2016;2016:4987436.
  23. Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.